IOVA IOVANCE BIOTHERAPEUTICS, INC.

Nasdaq iovance.com


$ 2.38 $ 0.12 (5.31 %)    

Thursday, 06-Nov-2025 15:18:12 EST
QQQ $ 614.75 $ -7.04 (-1.13 %)
DIA $ 470.52 $ -1.52 (-0.32 %)
SPY $ 672.80 $ -3.67 (-0.54 %)
TLT $ 89.70 $ 0.14 (0.16 %)
GLD $ 366.40 $ -0.86 (-0.23 %)
$ 1.81
$ 2.26
$ 2.38 x 4,865
$ 2.39 x 11,811
$ 2.10 - $ 2.51
$ 1.64 - $ 12.51
17,711,674
na
718.51M
$ 1.31
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 11-06-2025 09-30-2025 10-Q
2 08-07-2025 06-30-2025 10-Q
3 05-08-2025 03-31-2025 10-Q
4 02-27-2025 12-31-2024 10-K
5 11-07-2024 09-30-2024 10-Q
6 08-08-2024 06-30-2024 10-Q
7 05-09-2024 03-31-2024 10-Q
8 02-28-2024 12-31-2023 10-K
9 11-07-2023 09-30-2023 10-Q
10 08-08-2023 06-30-2023 10-Q
11 05-10-2023 03-31-2023 10-Q
12 02-28-2023 12-31-2022 10-K
13 11-03-2022 09-30-2022 10-Q
14 08-04-2022 06-30-2022 10-Q
15 05-05-2022 03-31-2022 10-Q
16 02-24-2022 12-31-2021 10-K
17 11-04-2021 09-30-2021 10-Q
18 08-05-2021 06-30-2021 10-Q
19 05-06-2021 03-31-2021 10-Q
20 02-25-2021 12-31-2020 10-K
21 11-05-2020 09-30-2020 10-Q
22 08-06-2020 06-30-2020 10-Q
23 05-05-2020 03-31-2020 10-Q
24 02-25-2020 12-31-2019 10-K
25 11-04-2019 09-30-2019 10-Q
26 08-01-2019 06-30-2019 10-Q
27 05-07-2019 03-31-2019 10-Q
28 02-28-2019 12-31-2018 10-K
29 11-06-2018 09-30-2018 10-Q
30 08-07-2018 06-30-2018 10-Q
31 05-10-2018 03-31-2018 10-Q
32 03-12-2018 12-31-2017 10-K
33 11-02-2017 09-30-2017 10-Q
34 08-03-2017 06-30-2017 10-Q
35 05-03-2017 03-31-2017 10-Q
36 03-09-2017 12-31-2016 10-K
37 11-04-2016 09-30-2016 10-Q
38 08-09-2016 06-30-2016 10-Q
39 05-09-2016 03-31-2016 10-Q
40 03-11-2016 12-31-2015 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 iovance-biotherapeutics-affirms-fy2025-sales-guidance-of-250000m-300000m-vs-264918m-est

Iovance Biotherapeutics (NASDAQ:IOVA) affirms FY2025 sales outlook from $250.000 million-$300.000 million to $250.000 million-$...

 iovance-biotherapeutics-q3-eps-025-beats-026-estimate-sales-67455m-miss-72402m-estimate

Iovance Biotherapeutics (NASDAQ:IOVA) reported quarterly losses of $(0.25) per share which beat the analyst consensus estimate ...

 iovance-biotherapeutics-interim-data-from-phase-2-iov-lun-202-trial-of-lifileucel-monotherapy-for-previously-treated-patients-with-advanced-nonsquamous-nsclc-without-actionable-genetic-mutations-showed-26-objective-response-rate

The objective response rate (ORR) was 25.6% by RECIST v1.1 following one-time treatment with lifileucel monotherapy in patients...

 hc-wainwright--co-maintains-buy-on-iovance-biotherapeutics-lowers-price-target-to-9

HC Wainwright & Co. analyst Joseph Pantginis maintains Iovance Biotherapeutics (NASDAQ:IOVA) with a Buy and lowers the p...

 iovance-biotherapeutics--enters-amended-sale-agreement-with-jefferies-may-sell-up-to-350m-of-common-stock

-SEC Filing

 hc-wainwright--co-reiterates-buy-on-iovance-biotherapeutics-maintains-20-price-target

HC Wainwright & Co. analyst Joseph Pantginis reiterates Iovance Biotherapeutics (NASDAQ:IOVA) with a Buy and maintains $...

 iovance-biotherapeutics-receives-health-canada-nocc-for-amtagvi

First T cell therapy for a solid tumor cancer and first treatment option approved in Canada for advanced melanoma after anti-PD...

 wells-fargo-maintains-overweight-on-iovance-biotherapeutics-lowers-price-target-to-14

Wells Fargo analyst Yanan Zhu maintains Iovance Biotherapeutics (NASDAQ:IOVA) with a Overweight and lowers the price target ...

 chardan-capital-maintains-buy-on-iovance-biotherapeutics-lowers-price-target-to-20

Chardan Capital analyst Geulah Livshits maintains Iovance Biotherapeutics (NASDAQ:IOVA) with a Buy and lowers the price targ...

 iovance-biotherapeutics-declines-29-in-premarket-trading-heres-whats-happening

Iovance stock fell over 29% pre-market after Q2 results, despite reporting a strong revenue jump led by Amtagvi sales.

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION